SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 12, Issue 1, 2018, Pages 59-63

  Filippatos, T D ^a   Tsimihodimos, V ^a   Liamis, G ^a   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular disease; Electrolytes; Magnesium; Phosphate; Potassium; SGLT2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; IPRAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; ELECTROLYTE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

BONE DENSITY; DISEASE ASSOCIATION; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE DISTURBANCE; FRACTURE; HUMAN; MAGNESIUM BLOOD LEVEL; MEDLINE; META ANALYSIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; ANTAGONISTS AND INHIBITORS; BLOOD; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS;

BENZHYDRYL COMPOUNDS; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; ELECTROLYTES; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC DISEASES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85027511295     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2017.08.003     Document Type: Review

References (35)

1. Tsimihodimos, V., Filippatos, T.D., Elisaf, M.S., Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opin Drug Metab Toxicol 13 (2017), 399–408.
2. Tsimihodimos, V., Filippatos, T.D., Filippas-Ntekouan, S., Elisaf, M., Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition. Curr Vasc Pharmacol 15 (2017), 96–102.
3. Filippatos, T.D., Liberopoulos, E.N., Elisaf, M.S., Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 6 (2015), 29–41.
4. Tang, H., Zhang, X., Zhang, J., Li, Y., Del Gobbo, L.C., Zhai, S., et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 59 (2016), 2546–2551.
5. Weir, M.R., Kline, I., Xie, J., Edwards, R., Usiskin, K., Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 30 (2014), 1759–1768.
6. Gilbert, R.E., Mende, C., Vijapurkar, U., Sha, S., Davies, M.J., Desai, M., Effects of canagliflozin on serum magnesium in patients with type 2 diabetes mellitus: a post hoc analysis of randomized controlled trials. Diabetes Ther 8 (2017), 451–458.
7. Mende, C.W., Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Curr Med Res Opin 33 (2017), 541–551.
8. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
9. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017, 10.1056/NEJMoa1611925 Epub ahead of print.
10. Gommers, L.M., Hoenderop, J.G., Bindels, R.J., de Baaij, J.H., Hypomagnesemia in type 2 diabetes: a vicious circle?. Diabetes 65 (2016), 3–13.
11. Nair, A.V., Hocher, B., Verkaart, S., van Zeeland, F., Pfab, T., Slowinski, T., et al. Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. Proc Natl Acad Sci U S A 109 (2012), 11324–11329.
12. van der Wijst, J., Bindels, R.J., Hoenderop, J.G., Mg2+ homeostasis: the balancing act of TRPM6. Curr Opin Nephrol Hypertens 23 (2014), 361–369.
13. Takayanagi, K., Shimizu, T., Tayama, Y., Ikari, A., Anzai, N., Iwashita, T., et al. Downregulation of transient receptor potential M6 channels as a cause of hypermagnesiuric hypomagnesemia in obese type 2 diabetic rats. Am J Physiol Renal Physiol 308 (2015), F1386–97.
14. Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T.V., Tripathy, D., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124 (2014), 509–514.
15. Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
16. Merovci, A., Mari, A., Solis, C., Xiong, J., Daniele, G., Chavez-Velazquez, A., et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab 100 (2015), 1927–1932.
17. Abdul-Ghani, M.A., Norton, L., DeFronzo, R.A., Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol 309 (2015), F889–F900.
18. Bankir, L., Bouby, N., Blondeau, B., Crambert, G., Glucagon actions on the kidney revisited: possible role in potassium homeostasis. Am J Physiol Renal Physiol 311 (2016), F469–F486.
19. Xu, L.H., Maalouf, N.M., Effect of acute hyperinsulinemia on magnesium homeostasis in humans. Diabetes Metab Res Rev, 2017, 33.
20. Kimura, G., Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. J Am Soc Hypertens 10 (2016), 271–278.
21. Ellison, D.H., Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes. Am J Physiol Renal Physiol 279 (2000), F616–F625.
22. Dyckner, T., Wester, P.O., Widman, L., Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. Eur J Clin Pharmacol 30 (1986), 535–540.
23. Gao, X., Peng, L., Adhikari, C.M., Lin, J., Zuo, Z., Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 13 (2007), 170–177.
24. Barnett, A.H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H.J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
25. Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85 (2014), 962–971.
26. Yavin, Y., Mansfield, T.A., Ptaszynska, A., Johnsson, K., Parikh, S., Johnsson, E., Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther 7 (2016), 125–137.
27. Palmer, B.F., Clegg, D.J., Physiology and pathophysiology of potassium homeostasis. Adv Physiol Educ 40 (2016), 480–490.
28. Dandona, P., Chaudhuri, A., Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: an overview for the primary care physician. Int J Clin Pract, 2017, 71.
29. Taylor, S.I., Blau, J.E., Rother, K.I., Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3 (2015), 8–10.
30. Bode, B., Stenlof, K., Harris, S., Sullivan, D., Fung, A., Usiskin, K., et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab 17 (2015), 294–303.
31. Bilezikian, J.P., Watts, N.B., Usiskin, K., Polidori, D., Fung, A., Sullivan, D., et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101 (2016), 44–51.
32. Watts, N.B., Bilezikian, J.P., Usiskin, K., Edwards, R., Desai, M., Law, G., et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101 (2016), 157–166.
33. Alba, M., Xie, J., Fung, A., Desai, M., The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin 32 (2016), 1375–1385.
34. Tang, H.L., Li, D.D., Zhang, J.J., Hsu, Y.H., Wang, T.S., Zhai, S.D., et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 18 (2016), 1199–1206.
35. Blevins, T.C., Farooki, A., Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgrad Med 129 (2017), 159–168.